← Back to Search

Incentive-Based Intervention for Substance Abuse Disorders

Phase 2

Recruiting

Led By Mindy Waite, PhD

Research Sponsored by Aurora Health Care

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Are in residential, day (PHP), partial day (IOP), or outpatient (OP) AODA treatment

Age at least 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 weeks

Awards & highlights

Study Summary

This trial will test whether offering people with substance abuse disorders incentive payments for healthy behaviors helps them combat their addiction.

Who is the study for?

This trial is for adults over 18 who have used opioids, cocaine, or methamphetamine non-medically in the last 21 days. Participants must be currently receiving some form of substance abuse treatment and meet specific medical criteria for substance use disorders. They need to have a smartphone with a data plan, an email they can access on their phone, and be willing to download and use the DynamiCare app.Check my eligibility

What is being tested?

The study tests two incentive-based approaches using an app called DynamiCare to promote abstinence from drug use among individuals with opioid or cocaine addiction. One approach increases rewards over time (escalating), while the other decreases them (de-escalating) as participants demonstrate continued abstinence.See study design

What are the potential side effects?

Since this trial involves behavioral interventions through an app rather than medications, there are no direct physical side effects like those associated with drugs. However, participants may experience psychological effects related to changes in behavior due to the incentives.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am currently in a substance abuse treatment program.

Select...

I am 18 years old or older.

Select...

I have a smartphone with a data plan and can download the DynamiCare app.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Abstinence from Opioid and/or Cocaine Use

Secondary outcome measures

Negative Saliva Analysis Frequency

Negative Urinalysis Frequency

Psychotherapy Completion

Trial Design

7Treatment groups

Experimental Treatment

Active Control

Group I: Escalating LowExperimental Treatment1 Intervention

Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every negative drug test up to a ceiling and "reset" to the lowest amount when a test is positive or missed. The "Low" group will receive incentives worth $2-$8.

Group II: Escalating HighExperimental Treatment1 Intervention

Group III: De-Escalating LowExperimental Treatment1 Intervention

Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The "Low" group will receive incentives worth $6-12.

Group IV: De-Escalating HighExperimental Treatment1 Intervention

Participants will have access to the DynamiCare app. Through the app, participants will receive incentive amounts for drug negative saliva tests. Incentive amounts increase with every positive drug tests (up to a ceiling), and decrease by the same increment with every negative drug test (down to a floor). The "High" group will receive incentives worth $10-$20.

Group V: Constant LowExperimental Treatment1 Intervention

In the Constant groups, incentive amounts will remain unchanged across time. The "Low" group will receive incentives worth $8 every test.

Group VI: Constant HighExperimental Treatment1 Intervention

In the Constant groups, incentive amounts will remain unchanged across time. The "High" group will receive incentives worth $16.

Group VII: ControlActive Control1 Intervention

Participants in this group will have access to the DynamiCare app; however, no behavioral incentives will be provided to this group.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Aurora Health CareLead Sponsor

43 Previous Clinical Trials

15,585 Total Patients Enrolled

University of ChicagoOTHER

1,004 Previous Clinical Trials

819,177 Total Patients Enrolled

University of California, Santa CruzOTHER

4 Previous Clinical Trials

1,521 Total Patients Enrolled

Media Library

App-Based Contingency Management Clinical Trial Eligibility Overview. Trial Name: NCT04927143 — Phase 2

Opioid Use Disorder Research Study Groups: Constant Low, De-Escalating High, Escalating High, De-Escalating Low, Control, Escalating Low, Constant High

Opioid Use Disorder Clinical Trial 2023: App-Based Contingency Management Highlights & Side Effects. Trial Name: NCT04927143 — Phase 2

App-Based Contingency Management 2023 Treatment Timeline for Medical Study. Trial Name: NCT04927143 — Phase 2

Opioid Use Disorder Patient Testimony for trial: Trial Name: NCT04927143 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the sample size of this medical trial?

"Assertion is accurate. Clinicaltrials.gov provides evidence that the trial, which was initially posted on September 15th 2021, is actively recruiting 600 patients from 3 distinct locations."

Answered by AI

Is App-Based Contingency Management a safe and effective treatment for patients?

"Power's team has assigned App-Based Contingency Management a score of 2 on their safety scale due to the lack of data indicating efficacy, although clinical evidence does demonstrate its relative security."

Answered by AI

Are there still opportunities for participants to join this clinical experiment?

"The details published on clinicaltrials.gov confirm that enrollment is currently open for this medical trial, which was first advertised in September 2021 and last updated in November 2022."

Answered by AI